Back to Agenda
Session 2, Track A: Health Canada and International Collaboration Initiatives
Session Chair(s)
My Dang, MBA
Director/Consultant, Regulatory Affairs
Cencora, Canada
The drive to bring medicines to emerging markets faster and aligning regulatory requirements across health agencies, such Health Canada and ANVISA has catapulted. In this interactive plenary session, we will dive into international collaboration efforts with emphasis on the surge in ANVISA activities to be at the forefront of the emerging market. We have leading representatives from Health Canada, ANVISA (Agencia Nacional de Vigilancia Sanitara) and USP (United States Pharmacopoeia) involved in International Collaborative initiatives to provide overview of collaborative work efforts, their challenges and a vision of the direction of these initiatives. The session will begin with presentations from several perspectives: Health Canada and its international collaboration programs; ANVISA and their growth in international partnerships; and USP’s pharmacopeial harmonization efforts. Following these overviews, attendees will have the opportunity to engage in an interactive discussion with the session moderator and speakers.
Learning Objective : - Explain the various international collaboration initiatives enabling access to quality medicine from Health Canada, ANVISA and USP
- Share perspectives on real and perceived barriers to international collaborative initiatives
- Illustrate successes and challenges with building converging practices and establishing a pathway for information-sharing initiatives
- Gain a global perspective of new collaborative efforts and understanding of future directions
Speaker(s)
Speaker
Maxime Sasseville, PhD, MSc
Health Canada, Canada
Manager
Speaker
Patricia Oliveira Pereira Tagliari, LLM, MPH
ANVISA, Brazil
Associate Director of the Second Directorate
Speaker
Christopher Colwell, MPA
US Pharmacopeia, United States
Vice President, International Government and Regulatory Affairs
Have an account?